Company
Eli Lilly
Eli Lilly and Company
Public (NYSE:LLY) · Indianapolis, Indiana, USA · Last verified Aug 15, 2024
Large-cap pharma with leading GLP-1/GIP franchise in diabetes and obesity.
Company profile
- Legal name
- Eli Lilly and Company
- Status
- public
- Ticker
- NYSE:LLY
- Headquarters
- Indianapolis, Indiana, USA
- Website
- www.lilly.com
Active assets
| Asset | Stage | Indications |
|---|---|---|
| Tirzepatide | Approved | — |
| Retatrutide | Phase 3 | — |
| Mazdutide | Phase 3 | — |
| Orforglipron | Phase 3 | — |
Trial roll-up
View all →| Registry ID | Phase | Title | Status |
|---|---|---|---|
| NCT03954834 | Phase 3 | A Study of Tirzepatide (LY3298176) Compared With Semaglutide in Participants With Type 2 Diabetes | Completed |
| NCT04159132 | Phase 3 | A Study of Tirzepatide for the Treatment of Obesity or Overweight in Participants Without Type 2 Diabetes | Completed |
| NCT05567796 | Phase 3 | A Study of Retatrutide in Participants With Obesity or Overweight | Recruiting |
Deals
View all →| Parties | Type | Headline value | Announced |
|---|---|---|---|
| Eli Lilly and Company / Chugai Pharmaceutical Co., Ltd. | licensing | Not disclosed (contingent) | Sep 10, 2018 |